Multicenter Randomized Single Blind Study of the Clinical Efficacy and Safety of GNR-060 (JSC "GENERIUM", Russia) Compared to Metalyse (Boehringer Ingelheim Pharma GmbH & Co.KG, Germany) in Patients With ST Elevation Myocardial Infarction

TNP-STEMI-III

GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST Elevation Myocardial Infarction (STEMI).

2021-09-03

2024-10-01

2024-10-01

Recruiting

Early phase I

244

Inclusion Criteria: * Myocardial infarction with elevation of the ST segment of the ECG (at point J) in 2 adjacent leads after no more than 6 hours from the onset of pain (lasting at least 20 minutes) in the chest (at the time of screening): * ≥ 2.5 mm in male ˂ 40 years, ≥ 2 mm in male ≥ 40 years, or ≥ 1.5 mm in female in leads V2-V3 and/or * ≥ 1 mm in other leads in the absence of left ventricular hypertrophy or left bundle branch block. Exclusion Criteria: * Diseases accompanied by significant bleeding, currently or within the last 6 months, hemorrhagic diathesis. * Current oral anticoagulant therapy with INR \> 1.3. * Diseases of the central nervous system at present or in history (neoplasm, aneurysm, surgery on the brain or spinal cord). * Severe uncontrolled arterial hypertension. * Major surgical interventions, biopsy of a parenchymal organ or significant trauma within the last 2 months (including trauma in combination with AMI at the present time), recent (within the last 3 months) traumatic brain injury. * Prolonged or traumatic cardiopulmonary resuscitation (\> 2 minutes) within the last 2 weeks. * Severe liver dysfunction, including liver failure, cirrhosis, portal hypertension (including esophageal varicose veins), active hepatitis. * Peptic ulcer of the stomach or duodenum in the acute stage. * Chronic kidney disease or other significant kidney disease with a decrease in glomerular filtration rate ≤30 ml / min / 1.73 m2. * Arterial aneurysm or presence of arterial/venous vascular malformation. * Neoplasm with an increased risk of bleeding. * Acute pericarditis and/or subacute bacterial endocarditis. * Acute pancreatitis. * Hypersensitivity to the active substance (tenecteplase), gentamicin (residual traces of the manufacturing process) or any excipient. * Hemorrhagic stroke or stroke of unknown etiology at present or in history. * Intracranial (including subarachnoid) hemorrhage at present or in history. * Ischemic stroke or transient ischemic attack (TIA) within the last 6 months. * Recent bleeding from the gastrointestinal or genitourinary tract or childbirth (within the last 10 days). * A recent (before 24 hours) puncture of an incompressible blood vessel (eg, subclavian or jugular vein). * Congenital and hereditary hemorrhagic coagulopathy (hemophilia, etc.) in history. * Pregnancy or breastfeeding. * Body mass index (BMI) less than 18.5 or more than 40 kg/m2. * Participation in another clinical trial currently or within 30 days prior to screening; use of any investigational drug within 30 days or 5 half-lives prior to screening.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'Single-blinded', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 244, 'type': 'ESTIMATED'}}

2024-03-06